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Abstract
Background
Regional and subtype-specific mutational patterns of HIV-1 transmitted drug resistance
(TDR) are essential for informing first-line antiretroviral (ARV) therapy guidelines and de-
signing diagnostic assays for use in regions where standard genotypic resistance testing is
not affordable. We sought to understand the molecular epidemiology of TDR and to identify
the HIV-1 drug-resistance mutations responsible for TDR in different regions and virus
subtypes.
Methods and Findings
We reviewed all GenBank submissions of HIV-1 reverse transcriptase sequences with or
without protease and identified 287 studies published between March 1, 2000, and Decem-
ber 31, 2013, with more than 25 recently or chronically infected ARV-naïve individuals.
These studies comprised 50,870 individuals from 111 countries. Each set of study se-
quences was analyzed for phylogenetic clustering and the presence of 93 surveillance
drug-resistance mutations (SDRMs). The median overall TDR prevalence in sub-Saharan
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Africa (SSA), south/southeast Asia (SSEA), upper-income Asian countries, Latin America/
Caribbean, Europe, and North America was 2.8%, 2.9%, 5.6%, 7.6%, 9.4%, and 11.5%,
respectively. In SSA, there was a yearly 1.09-fold (95%CI: 1.05–1.14) increase in odds of
TDR since national ARV scale-up attributable to an increase in non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) resistance. The odds of NNRTI-associated TDR also increased in
Latin America/Caribbean (odds ratio [OR] = 1.16; 95%CI: 1.06–1.25), North America (OR =
1.19; 95%CI: 1.12–1.26), Europe (OR = 1.07; 95% CI: 1.01–1.13), and upper-income Asian
countries (OR = 1.33; 95%CI: 1.12–1.55). In SSEA, there was no significant change in the
odds of TDR since national ARV scale-up (OR = 0.97; 95% CI: 0.92–1.02). An analysis limited
to sequences with mixtures at less than 0.5% of their nucleotide positions—a proxy for recent
infection—yielded trends comparable to those obtained using the complete dataset. Four
NNRTI SDRMs—K101E, K103N, Y181C, and G190A—accounted for>80% of NNRTI-asso-
ciated TDR in all regions and subtypes. Sixteen nucleoside reverse transcriptase inhibitor
(NRTI) SDRMs accounted for>69% of NRTI-associated TDR in all regions and subtypes. In
SSA and SSEA, 89% of NNRTI SDRMswere associated with high-level resistance to nevira-
pine or efavirenz, whereas only 27% of NRTI SDRMswere associated with high-level resis-
tance to zidovudine, lamivudine, tenofovir, or abacavir. Of 763 viruses with TDR in SSA and
SSEA, 725 (95%) were genetically dissimilar; 38 (5%) formed 19 sequence pairs. Inherent lim-
itations of this study are that some cohorts may not represent the broader regional population
and that studies were heterogeneous with respect to duration of infection prior to sampling.
Conclusions
Most TDR strains in SSA and SSEA arose independently, suggesting that ARV regimens
with a high genetic barrier to resistance combined with improved patient adherence may
mitigate TDR increases by reducing the generation of new ARV-resistant strains. A small
number of NNRTI-resistance mutations were responsible for most cases of high-level resis-
tance, suggesting that inexpensive point-mutation assays to detect these mutations may be
useful for pre-therapy screening in regions with high levels of TDR. In the context of a public
health approach to ARV therapy, a reliable point-of-care genotypic resistance test could
identify which patients should receive standard first-line therapy and which should receive a
protease-inhibitor-containing regimen.
Introduction
More than 10 million individuals in low- and middle-income countries (LMICs) are receiving
antiretroviral (ARV) therapy [1]. The global scale-up of ARV therapy has markedly reduced
HIV-1 mortality, mother-to-child transmission, and adult HIV-1 incidence [2–5]. These un-
precedented public health accomplishments were made possible by the availability and wide-
spread administration of inexpensive fixed-dose combinations of two nucleoside reverse
transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse transcriptase inhibitor
(NNRTI) [6,7].
However, the margin of long-term ARV treatment success in LMICs is narrow because
NNRTI-based regimens have a low genetic barrier to resistance. ARV treatment failure with a
fixed-dose NRTI/NNRTI combination occurs in 10% to 30% of patients per year [8–10], and
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most patients with virological failure acquire NRTI and/or NNRTI resistance [10–12]. As the
number of LMIC patients with acquired ARV resistance has increased, so has the proportion
of newly infected patients with transmitted drug resistance (TDR) [11,13,14].
Although both acquired and transmitted HIV-1 drug resistance are public health concerns,
TDR has the potential to more rapidly reverse the effectiveness of first-line ARV therapy at the
population level. Persons with TDR who begin ARV therapy with a lower genetic barrier to re-
sistance have a higher risk of virological failure [15–20]. Previous meta-analyses have examined
aggregate data from studies of TDR in different regions at different times but have not exam-
ined the virus sequences responsible for TDR. In this study, we performed an individual-pa-
tient-level meta-analysis to characterize the molecular epidemiology of transmitted HIV-1
drug-resistant variants and to identify the drug-resistance mutations most responsible for TDR
in different regions and virus subtypes.
Methods
Study Inclusion Criteria
We retrieved all published HIV-1 group M reverse transcriptase (RT) nucleic acid sequences,
with or without protease sequences, using a tblastn search of the GenBank nucleotide sequence
database v. 200 (released 2014-02-15). Retrieved sequences with the same GenBank “Author”
and “Title” fields were grouped into submission sets (or studies). We then read the GenBank
annotation and associated published papers to identify studies meeting the following two crite-
ria: (i) studies that described a population of25 ARV-naïve HIV-1-infected individuals char-
acterized by country, year of virus sampling, and method and site of recruitment, and (ii)
studies that contained sequences encompassing RT codons 40 to 240 determined by direct
PCR sequencing of plasma, peripheral blood mononuclear cells, or dried blood spots. Studies
of unrepresentative populations, such as those in which individuals were selected based on
knowledge of their ARV-resistance status, were excluded. Studies of children born to mothers
receiving ARV therapy were also excluded.
Studies meeting inclusion criteria were assigned to one of the following geo-economic re-
gions: (i) sub-Saharan Africa (SSA), (ii) LMICs of south/southeast Asia (SSEA), (iii) Latin
America and Caribbean, (iv) Europe, (v) United States, Canada, and Puerto Rico (North Amer-
ica), (vi) upper-income Asian countries, (vii) countries of the former Soviet Union (FSU), (viii)
North Africa, and (ix) Australia. For studies conducted in countries on different continents,
separate datasets for each continent were created, provided the study had more than 25 indi-
viduals per country.
Sequence Analyses
TDR was defined as the presence in ARV-naïve individuals of one or more mutations from the
WHO 2009 list of surveillance drug-resistance mutations (SDRMs) [21]. The SDRM list con-
sists of 93 drug-resistance mutations, including 34 NRTI-resistance mutations at 15 RT posi-
tions, 19 NNRTI-resistance mutations at ten RT positions, and 40 protease inhibitor (PI)–
resistance mutations at 18 protease positions. Thymidine-analog mutations (TAMs) were de-
fined as the NRTI SDRMs M41L, D67N/G/E, K70R, L210W, T215Y/F/S/C/D/E/I/V, and
K219Q/E/N/R. T215 mutations other than T215Y/F were called T215 revertants because they
often emerge in individuals initially infected with a virus containing T215Y/F [22,23].
The Calibrated Population Resistance (CPR) analysis tool (http://cpr.stanford.edu/cpr.cgi)
was used to calculate the proportions of individuals per study with overall and NRTI-, NNRTI-,
and PI-associated TDR [24]. CPR was also used for quality control, excluding sequences contain-
ing an excess of stop codons, highly ambiguous nucleotide calls, extensive G-to-A hypermutation,
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PLOSMedicine | DOI:10.1371/journal.pmed.1001810 April 7, 2015 4 / 29
or highly unusual amino acids. HIV-1 subtype was determined using the REGAHIV-1 Subtyping
Tool [25].
We also determined the proportion of bases containing electrophoretic evidence for a mix-
ture of two nucleotides. We then examined whether the median proportion of mixtures in a
study correlated with characteristics of the study population such as whether the study popula-
tion comprised individuals known to belong to groups likely to be recently infected, such as
primiparous women presenting for antenatal care. In subset analyses designed to include indi-
viduals more likely to have been recently infected, samples were classified as having a low
(<0.5%) or high (0.5%) proportion of mixtures based on previous studies showing that a
0.5% cutoff is useful for identifying recently infected individuals [26–28].
Temporal Changes in Prevalence of Transmitted Drug Resistance
For individual-patient-level meta-analyses, samples from different studies conducted in the
same region were pooled and a generalized linear mixed model was used to assess the effects of
national ARV scale-up on the presence or absence of any or NRTI-, NNRTI-, or PI-associated
TDR [29]. To account for study heterogeneity, we included study as a random effect in the
model using the R package lme4 [30]. We calculated the yearly increase in the odds of TDR
since ARV scale-up. We also assessed the associations of virus subtype, duration of HIV-1 in-
fection, recruitment site, and sample type with the odds of TDR while accounting for the num-
ber of years since national ARV scale-up. The year of each country’s national ARV scale-up
was obtained from UN General Assembly special session country reports. For regions other
than SSA and SSEA, we used sample year (rather than years since ARV scale-up) in the gener-
alized linear mixed model because in these regions ARVs were more often available to the gen-
eral population in the 1990s.
We also performed two subset analyses to assess the robustness of the overall model to two
sources of potential variation: the duration of infection prior to virus sequencing and the na-
ture of patient recruitment. In the first subset analysis, we performed generalized linear mixed
regression using only virus sequences with mixtures at less than 0.5% of their nucleotide posi-
tions—a proxy for recent infection. In the second subset analysis, we performed generalized
linear mixed regression using the subset of studies in which participants were sequentially
recruited.
Mutation Analyses
We compared the proportions of each SDRM in sequences from the seven most common
HIV-1 subtypes (subtypes A, B, C, D, G, CRF01_AE, and CRF02_AG) and from individuals
from SSA, SSEA, Latin America/Caribbean, and the pooled upper-income countries of North
America, Europe, and Asia using Fisher’s exact test. Holm’s method was used to control the
family-wise error rate for multiple hypothesis testing: associations with adjusted p< 0.05 were
considered statistically significant. Statistically significant associations are reported, along with
their original unadjusted p-values.
We used Spearman’s rank correlation test to assess the correlation of the relative ranking of
the proportions of each NRTI, NNRTI, and PI SDRM in SSA, SSEA, Latin America/Caribbean,
and the pooled upper-income countries with the proportions of these mutations in HIV-1 se-
quences from ARV-experienced individuals from these regions in the Stanford University HIV
Drug Resistance Database (HIVDB). For this analysis, we excluded all sequences from studies
of ARV-experienced individuals selected on the basis of their patterns of drug-resistance muta-
tions. The numbers of included NRTI-treated individuals were 4,522 (SSA), 2,218 (SSEA),
4,164 (Latin America/Caribbean), and 13,522 (pooled upper-income countries). The numbers
Surveillance of Transmitted HIV-1 Drug Resistance
PLOSMedicine | DOI:10.1371/journal.pmed.1001810 April 7, 2015 5 / 29
of NNRTI-treated individuals were 4,959 (SSA), 1,994 (SSEA), 3,677 (Latin America/Caribbe-
an), and 8,927 (pooled upper-income countries). The numbers of PI-treated individuals were
717 (SSA), 103 (SSEA), 4,107 (Latin America/Caribbean), and 9,985 (pooled upper-income
countries). We also analyzed the correlation between the presence of an SDRM in a sequence
and the estimated level of drug resistance for that sequence according to the HIVDB genotypic
resistance interpretation system [31].
Molecular Epidemiology
A neighbor-joining tree of each study’s sequences was created using genetic distances comput-
ed using the HKY85 substitution model with a gamma distribution to model site rate variation.
By traversing the tree, we identified sets of closely related sequences for which the median ge-
netic distance was0.015. An SDRM cluster was defined as a set of three or more closely relat-
ed sequences containing identical SDRMs. Trees were constructed using PAUP and traversed
using R packages ape and igraph [32]. The program BEAST (Bayesian Evolutionary Analysis
by Sampling Trees) was used to identify extended lineages of sequence clusters with the same
SDRMs [33].
For each study, we calculated a sequence dissimilarity index, which we defined as the num-
ber of sequence clusters plus unclustered sequences divided by the total number of sequences.
Using this approach, studies without any closely related sequences had a sequence dissimilarity
index of 100%. To assess the impact of closely related sequences on the proportion of individu-
als with TDR, we recalculated this proportion counting closely related sequences with identical
SDRMs just once, assuming these reflected transmission of resistant viruses among ARV-naïve
patients. We then recalculated the TDR prevalence in each study to yield an estimate reflecting
transmission from ARV-treated to ARV-naïve individuals.
Results
Studies and Individuals
The February 2014 GenBank tblastn search yielded 1,707 studies of HIV-1 group M RT se-
quences, with or without protease sequences. Of these studies, 340 described a population of
25 ARV-naïve individuals. Fifty-three of the 340 studies were excluded: 22 described an un-
representative subset of a larger population, 15 included children in a program for prevention
of mother-to-child transmission, nine included samples sequenced using a method other than
direct PCR sequencing, and seven did not include sample years. Additionally, 111 individuals
were excluded because their sequences did not meet sequence quality inclusion criteria. Finally,
sequences from 50,870 ARV-naïve individuals in 287 studies were included in our analysis
(Fig 1; S1 Table).
For 277 (97%) studies, annotation was obtained from an accompanying peer-reviewed pub-
lication. For ten (3%) studies, annotation was obtained from the GenBank record and the se-
quence contributors. The primary goal for 221 (77%) studies was to estimate TDR prevalence.
The primary goal for 62 (22%) was to characterize sequence diversity for molecular epidemio-
logic purposes or vaccine development. Four (1%) studies contained pre-therapy samples from
patients enrolling in a clinical trial.
For 238 (83%) of the studies, the sample year of each sequence was reported. For 49 (17%)
of the studies, a range of sample years was reported for the study population rather than for
each individual, and the median of the range was assigned to each sample. Sequences were ob-
tained from plasma, peripheral blood mononuclear cells, and dried blood spots in 252 (88%),
29 (10%), and six (2%) studies, respectively. Both RT and protease were sequenced in 272
(95%) studies; only RT was sequenced in 15 (5%) studies.
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In 211 (73.5%) studies, cohorts were composed of sequentially recruited individuals charac-
terized by region, time period, and site of recruitment. In 21 (7.3%) studies, cohorts were a ran-
dom subset of sequentially recruited individuals characterized by region, time period, and site
of recruitment. Thus, overall, participants from 232 (80.8%) studies were sequentially re-
cruited. In 47 (16.4%) studies, participants were not sequentially recruited but rather were an
unbiased subset of available samples from individuals characterized by region, time period, and
site of recruitment. In six (2.1%) studies, the method of participant recruitment was not pro-
vided. In two (0.7%) studies, participants were recruited using respondent-driven sampling.
Fig 1. Flow chart showing the derivation of study sets meetingmeta-analysis inclusion criteria: studies of representative ARV-naïve populations
of 25 or more individuals with published RT sequences with or without protease sequences.
doi:10.1371/journal.pmed.1001810.g001
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ARV-Naïve Population Characteristics by Region
There was a median of 91 individuals per study (interquartile range [IQR]: 49–174). Ninety-
five (33%) of 287 studies were conducted in SSA (11,536 individuals; 32 countries), 56 (20%) in
SSEA (6,522 individuals; seven countries), 42 (15%) in Europe (11,802 individuals; 30 coun-
tries), 38 (13%) in Latin America/Caribbean (5,628 individuals; 20 countries), 27 (9%) in
North America (9,283 individuals; four countries), 12 (4%) in the upper-income countries of
Asia (4,950 individuals; five countries), 12 (4%) in FSU countries (1,365 individuals; nine coun-
tries), three (1%) in North Africa (157 individuals; three countries), and two (1%) in Australia
(627 individuals). Table 1 summarizes the epidemiologic characteristics and virus subtypes,
and Table 2 summarizes the median TDR prevalence by ARV class in the seven most common-
ly studied regions. The epidemiologic characteristics, TDR prevalence, CPR analysis, and link
to each study publication can be accessed using an interactive map on the HIVDB website
(http://hivdb.stanford.edu/surveillance/map/; Fig 2).
The populations studied in SSA and SSEA were primarily from specialized clinics, includ-
ing antenatal clinics, voluntary counseling and testing centers, blood donation centers, sexually
transmitted disease clinics, and tuberculosis clinics. The populations studied in Latin America/
Caribbean and the upper-income countries were primarily from HIV clinics. Thirty-five (12%)
of the 287 studies consisted entirely of individuals with recent HIV-1 infection, including 10%
(15) of the 151 studies in SSA and SSEA and 25% (17) of the 69 of studies in Europe and North
America. Of the 21 WHO TDR surveillance studies for which sequences were available, 20
were conducted in SSA and SSEA.
The proportion of mixed nucleotide positions per sequence was significantly lower in the
samples from the 35 studies consisting entirely of recently infected persons compared with the
Table 1. Epidemiologic characteristics in seven geo-economic regions.
Characteristic SSA SSEA Latin
America/
Caribbean
Europe North America Upper-
Income Asia
FSU
Number of studies 95 56 38 42 27 12 12
Number of individuals 11,536 6,522 5,628 11,802 9,283 4,950 1,365
Median number
individuals per study
(IQR)
72 (39–122) 76 (46–123) 82 (50–119) 122 (66–213) 274 (66–675) 339 (68–504) 101 (46–153)
Number of countries 32 7 20 30 4 5 9
Most common
countries (number of
studies)
ZA (19),UG (13),
CM (13)
CN (22),VN
(12),IN (11)
BR (24),AR
(3),MX (3)
ES (12),IT (7),
SE (5)
US (21),CA (9),
PR (2)
KR (5),JP (4),
TW (2)
EE (3),RU (3),
UA (2)
Median sample year
(IQR)
2007(2004–2008) 2008(2007–
2009)
2007(2002–
2008)
2005(2003–
2006)
2003(1999–
2006)
2005(2004–
2007)
2003(2002–
2008)
Most common
recruitment sites
(number of studies)
VCT/ANC/BD/
STD/TB (52);
HIVC (29)
VCT/ANC/BD
(14);HIVC (20)
HIVC (23);
VCT/BD (9)
HIVC HIVC (14);BD
(5);VCT (1)
HIVC (8) VCT/HIVC
Most common virus
subtypes (percent
individuals)
C (42%),A
(17%),02 (17%)
01 (66%),C
(15%),B (13%)
B (83%),C
(9%)
B (67%),C
(7%),G (7%)
B (97%) B (84%),01
(10%)
A (57%),06
(29%),B (9%)
Latin America/Caribbean includes three studies from Caribbean countries. Three studies from North Africa and two studies from Australia are not included
in this table but are summarized in S1 Table. Country abbreviations: AR, Argentina; BR, Brazil; CA, Canada; CM, Cameroon; CN, China; EE, Estonia; ES,
Spain; IN, India; IT, Italy; JP, Japan; KR, Republic of Korea; MX, Mexico; PR, Puerto Rico; RU, Russia; SE, Sweden; TW, Taiwan; UA, Ukraine; UG,
Uganda; VN, Viet Nam; ZA, South Africa. Recruitment site abbreviations: ANC, antenatal clinics; BD, blood donation centers; HIVC, HIV clinics; STD,
sexually transmitted disease clinics; TB, tuberculosis clinics; VCT, voluntary counseling and testing centers.
doi:10.1371/journal.pmed.1001810.t001
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remaining studies (median 0% versus 0.23% mixtures per sample, p< 0.001, Wilcoxon rank
sum test). Among these remaining studies, the proportion of mixed nucleotide positions per se-
quence was significantly lower among blood donors (median 0.08% mixtures per sample), vol-
untary counseling and testing center attendees (0.22% mixtures per sample), and antenatal
clinic attendees (0.28% mixtures per sample) compared with those presenting to an HIV clinic
(0.41% mixtures per sample; p< 0.001 for each comparison, Wilcoxon rank sum test).
SSA had the most diverse virus subtypes, with C (4,849 viruses; 42%), A (1,991 viruses; 17%),
and CRF02_AG (1,982 viruses; 17%) accounting for more than 75% of 11,536 viruses. In SSEA,
CRF01_AE (4,270 viruses; 66%), C (1,006 viruses; 15%), and B (856 viruses; 13%) accounted for
95% of 6,522 viruses. In North America, Europe, Latin America/Caribbean, and the upper-in-
come Asian countries, most samples had subtype B viruses (range: 67%–97%). Of 1,365 viruses
from FSU countries, the most common subtype was A (783 viruses; 57%).
Regional Transmitted Drug Resistance Prevalence
The median study-level TDR prevalence ranged from 2.8% and 2.9% in 95 SSA studies and 56
SSEA studies, respectively, to 9.4% and 11.5% in 42 Europe studies and 27 North America stud-
ies, respectively (Table 2). Genotypic evidence of two-class TDR was present in 0.6% (69 of
11,536), 0.6% (41 of 6,522), 1.4% (79 of 5,628), and 1.2% (312 of 25,035) of individuals from
SSA, SSEA, Latin America/Caribbean, and the pooled upper-income countries, respectively.
Genotypic evidence of three-class TDR was present in 0.03% (three of 11,536), 0.04% (three of
6,522), 0.2% (11 of 5,628), and 0.3% (86 of 25,035) of individuals from SSA, SSEA, Latin Amer-
ica and the pooled upper-income countries, respectively.
In 25 of the 95 studies in SSA, most samples were obtained before the national ARV scale-
up (median 2 y before scale-up; range: 0–7 y). The median TDR prevalence in these 25 pre-
scale-up studies was 2.1% (IQR: 0%–3.3%). In four (15%) of the 25 pre-scale-up studies, TDR
prevalence was above 5%. For the remaining 70 post-scale-up studies (median 4 y after scale-
up; range: 1–12 y), the median TDR prevalence was 3.2% (IQR: 1.9%–5.7%). In 23 (33%) of the
70 post-scale-up studies, TDR prevalence was above 5%.
In seven of the 56 studies in SSEA, most samples were obtained before the national ARV
scale-up (median 2 y before scale-up; range: 0–7 y). The median TDR prevalence in these seven
pre-scale-up studies was 2.9% (IQR: 1.0%–5.1%). In two (29%) of the seven studies, TDR prev-
alence was above 5%. For the remaining 49 post-scale-up studies (median 4 y after scale-up;
range: 1–9 y), the median TDR prevalence was 3.0% (IQR: 1.9–5.3%). In 15 (31%) of the 49
post-scale-up studies, TDR prevalence was above 5%.
Table 3 shows the odds ratios (ORs) for the yearly change in the proportion of individuals
with TDR by general linear mixed regression modeling by year since ARV scale-up in SSA and
Table 2. Study-level estimates of transmitted drug resistance in seven geo-economic regions.
TDR SSA
(n = 95)
SSEA
(n = 56)
Latin America/
Caribbean (n = 38)
Europe (n = 42) North America (n = 27) Upper-Income
Asia (n = 12)
FSU (n = 12)
Overall 2.8% (1.3%–5.6%) 2.9% (1.8%–5.3%) 7.6% (3.9%–10.2%) 9.4% (6.1%–15.1%) 11.5% (8.3%–14.6%) 5.6% (3.5%–9.0%) 4.0% (0%–6.4%)
NRTI 0% (0%–2.4%) 1% (0%–2.4%) 4% (1.8%–6.6%) 5.6% (3.1%–10.1%) 5.8% (3.4%–8.2%) 3.5% (1.5%–5.0%) 1.8% (0%–3.9%)
NNRTI 1.4% (0%–2.8%) 0.8% (0%–2.1%) 2.8% (1.1%–5.0%) 3.4% (1.5%–5.3%) 4.5% (3.0%–6.8%) 1.1% (0.2%–1.6%) 0.8% (0%–2.1%)
PI 0% (0%–1.4%) 0.5% (0%–1.9%) 1.4% (0%–3.0%) 1.5% (0%–2.8%) 3.0% (2.3%–3.9%) 1.6% (0.6%–3.0%) 0.2% (0%–2.1%)
Data are median (IQR) of study-level prevalence of individuals with any (overall) and NRTI-, NNRTI-, and PI-associated SDRMs by region; the number of
studies conducted is indicated for each region (n). Latin America/Caribbean includes three studies from Caribbean countries. Three studies from North
Africa and two studies from Australia are not included in this table but are summarized in S1 Table.
doi:10.1371/journal.pmed.1001810.t002
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SSEA and by sample year in the remaining regions. In SSA, there was a significant yearly
1.09-fold (95% CI: 1.05–1.14) increase in the odds of overall TDR, accompanied by an increase
in NRTI-associated and NNRTI-associated TDR (Table 3; Fig 3). In SSEA, there was no signifi-
cant trend over time in overall, NRTI-associated, or NNRTI-associated TDR (Table 3; Fig 4).
There was a yearly 1.15-fold (95% CI: 1.07–1.23), 1.06-fold (95% CI: 1.00–1.11), and
1.05-fold (95% CI: 1.02–1.09) increase in the odds of overall TDR in the upper-income Asian
countries, Latin America/Caribbean, and North America, respectively (Table 3). In Latin
America/Caribbean and North America, the increase in overall TDR was accompanied by an
increase in NNRTI-associated TDR (Figs 5 and 6). In the upper-income countries of Asia, the
increase in the odds of overall TDR was accompanied by an increase in NNRTI- and PI-associ-
ated TDR (Fig 7). The temporal increase in the odds of PI-associated TDR in this region was
partly attributable to two extended lineages in Japan published in two studies [25,26], one con-
taining 30 individuals with viruses containing M46I alone and another containing 16 individu-
als with viruses containing M46L alone (S1 and S2 Figs).
In Europe, there was a marginal yearly decrease in the odds of overall TDR (OR = 0.97; 95%
CI: 0.93–1.00), accompanied by a yearly decrease in NRTI-associated TDR (OR = 0.93; 95%
CI: 0.90–0.93) and a yearly increase in NNRTI-associated TDR (OR = 1.07; 95% CI: 1.01–1.13)
(Fig 8). The decrease in overall TDR partly reflected the high levels of TDR in this region prior
to 2000, in that a time trend analysis using only those virus samples obtained after 2000 did not
show a significant change in the odds of overall TDR. In addition, the decrease resulted from a
temporal increase in the proportion of viruses belonging to non-B subtypes, which were more
likely to be from immigrants from LMICs. After adjusting for the presence of subtype B versus
non-B subtypes, there was no yearly decrease in the odds of overall TDR, and the non-subtype-
Fig 2. A snapshot of an interactive map plotting the prevalence of transmitted drug resistance in 111
countries from 287 studies between 2000 and 2013 (http://hivdb.stanford.edu/surveillance/map/).
Each study is represented by a circle. The size of the circle is proportional to the number of individuals in the
study. The circle color indicates the prevalence of overall TDR in the study: white (<2.5%), pale yellow (2.5%
to 4.9%), orange (5.0% to 9.9%), and red (10.0%). Each study can also be located on a sidebar, which lists
each publication, percent overall TDR, number of individuals, and the country (or countries) where the study
was conducted. Clicking on a sidebar row or a study circle in the interactive version of the map at http://hivdb.
stanford.edu/surveillance/map/ generates a pop-up box with additional information including a link to the
appropriate PubMed reference, the TDR prevalence by ARV class, the median year of virus sampling, the
source of virus isolation, the mechanism of participant recruitment, and the virus subtype distribution (a pop-
up box of the study Bila13 is shown as an example). The complete set of data associated with a study can be
reviewed by clicking on the “Resistance (%)” link either on the sidebar or within the study circle pop-up menu.
doi:10.1371/journal.pmed.1001810.g002
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B viruses in Europe had significantly lower odds of TDR in any given year (OR = 0.5; 95% CI:
0.43–0.6; p< 0.001) than subtype B viruses.
With the exception of the distinction between subtype B versus non-subtype-B viruses in
Europe, virus subtype in any region was not significantly associated with the odds of TDR, re-
gardless of whether or not the model was adjusted for years since ARV scale-up or sampling
year. An association between the duration of infection and the odds of TDR could not be ade-
quately assessed because too few individuals had documented recent HIV-1 infection. In SSA,
individuals recruited at a voluntary counseling and testing center (OR = 2.81; 95% CI: 1.92–
4.12; p< 0.001) or HIV clinic (OR = 1.94; 95% CI: 1.47–2.55; p< 0.001) were more likely to
Table 3. Yearly change in odds of transmitted drug resistance in generalized linear mixed regression
models in geo-economic regions with and without ARV scale-up.
Region Drug Class ORa (95% CI) p-Valuea
OR for years since ARV scale-upb
SSA(n = 11,536) Overall 1.09 (1.05–1.14) <0.001
NRTI 1.12 (1.05–1.19) <0.001
NNRTI 1.12 (1.07–1.17) <0.001
PI 1.04 (0.99–1.10) 0.1
SSEA(n = 6,522) Overall 0.97 (0.92–1.02) 0.3
NRTI 0.93 (0.87–1.00) 0.06
NNRTI 1.09 (0.99–1.21) 0.1
PI 0.97 (0.90–1.03) 0.4
OR for sample yearb
Latin America/Caribbean (n = 5,628) Overall 1.06 (1.00–1.11) 0.04
NRTI 0.99 (0.93–1.07) 0.9
NNRTI 1.16 (1.06–1.25) <0.001
PI 1.01 (0.95–1.07) 0.8
Europe(n = 10,802) Overall 0.97 (0.93–1.00) 0.05
NRTI 0.93 (0.90–0.93) <0.001
NNRTI 1.07 (1.01–1.13) 0.01
PI 0.99 (0.93–1.05) 0.7
North America(n = 9,283) Overall 1.05 (1.02–1.09) 0.003
NRTI 1.00 (0.96–1.05) 0.9
NNRTI 1.19 (1.12–1.26) <0.001
PI 1.00 (0.95–1.05) 0.9
Upper-income Asian countries(n = 4,950) Overall 1.15 (1.07–1.23) <0.001
NRTI 1.05 (0.96–1.13) 0.3
NNRTI 1.33 (1.12–1.55) <0.001
PI 1.28 (1.12–1.46) <0.001
Three studies from North Africa and two studies from Australia were excluded. Latin America/Caribbean
includes three studies from Caribbean countries.
aFor each region, a generalized linear mixed model was used to assess the yearly change in the odds (OR)
of TDR accounting for study heterogeneity using the R package lme4. The model included a categorical
outcome variable indicating the presence or absence of TDR and two explanatory variables: years since
scale-up (or the sample year) as a fixed-effect term and the study as a random-effect term.
bYearly change in the odds of TDR since ARV scale-up in regions with national ARV scale-up programs
and for each sample year in regions without national ARV scale-up; the number of individuals in each
region (n) is indicated.
doi:10.1371/journal.pmed.1001810.t003
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have TDR than individuals recruited at other sites. In all other regions, there was no association
between the odds of TDR and the recruitment site.
In SSA, SSEA, Latin America/Caribbean, Europe, North America, and the upper-income
countries in Asia, 59% (6,766 of 11,536), 70% (4,576 of 6,522), 64% (3,614 of 5,628), 53%
(6,312 of 11,802), 52% (4,853 of 9,283), and 72% (3,546 of 4,950) of virus sequences, respective-
ly, contained mixtures at less than 0.5% of their nucleotide positions—a proxy for recent infec-
tion. A subset analysis using only virus sequences with less than 0.5% mixtures corroborated
each of the trends in the main analysis (S2 Table).
A subset analysis using the 232 studies with sequentially recruited participants (80.8% of all
287 studies) corroborated each of the trends in the main analysis; the overall increase in TDR
in Latin America/Caribbean and the overall decrease in TDR in Europe were not statistically
significant in the subset analyses, even though the point estimates of the ORs were similar to
those seen in the analysis including all studies (S3 Table).
Correlation of Surveillance Drug-Resistance Mutations with Region
Of the 34 NRTI SDRMs, 16 occurred in0.1% of the 50,870 viruses from all regions: most
commonly M184V, the TAMs (M41L, D67G/N, K70R, L210W, T215F/Y, K219E/Q), the T215
revertants (T215C/D/E/S), T69D, and F77L. These 16 SDRMs comprised 234 (79%) of 298
NRTI SDRMs in SSA, 127 (69%) of 184 NRTI SDRMs in SSEA, 343 (90%) of 382 NRTI
SDRMs in Latin America/Caribbean, and 2,462 (90%) of 2,724 NRTI SDRMs in the pooled
upper-income countries. M184V and the TAMs were the most common NRTI SDRMs in all
four regions (S4 Table). L74I (4.4%; eight of 184), V75M (8.2%; 15 of 184), and M184I (3.8%;
Fig 3. Temporal trends in the yearly proportion of individuals having one or more surveillance drug-
resistance mutations in sub-Saharan Africa. The x-axes represent the number of years since ARV scale-
up for each isolate. The diameter of each circle is proportional to the number of samples sequenced that year.
The fitted line shows the fixed effect of years since ARV scale-up in generalized linear mixed model
regression.
doi:10.1371/journal.pmed.1001810.g003
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seven of 184) accounted for a higher proportion of the NRTI SDRMs in SSEA than in other re-
gions (<2% for each mutation in each of the other regions; p< 0.001). K70E (2.7%; eight of
298) accounted for a higher proportion of the NRTI SDRMs in SSA than in other regions
(<0.3% in each of the other regions; p< 0.001). The T215 revertants accounted for a higher
proportion of NRTI SDRMs in the pooled upper-income countries (25.2%; 685 of 2,724) and
Latin America/Caribbean (18.9%; 72 of 382) than in SSA (4.7%; 14 of 298; p< 0.001) or SSEA
(8.7%; 16 of 184; p< 0.001).
Of the 19 NNRTI SDRMs, four mutations—K101E, K103N, Y181C, and G190A—occurred
in0.1% of the 50,870 viruses from all regions. These four SDRMs comprised 80% or more of
the NNRTI SDRMs in each of the four regions: 86% (264) of 306 NNRTI SDRMs in SSA, 81%
(110) of 136 NNRTI SDRMs in SSEA, 81% (164) of 205 NNRTI SDRMs in Latin America/Ca-
ribbean, and 80% (910) of 1,140 NNRTI SDRMs in the pooled upper-income countries.
K103N was the most common NNRTI SDRM in each region except for SSEA, accounting for
45% (137) of 306 NNRTI SDRMs in SSA, 49% (164) of 205 NNRTI SDRMs in Latin America/
Caribbean, and 54% (612) of 1,140 NNRTI SDRMs in the pooled upper-income countries (S5
Table). Y181C was the most common NNRTI SDRM in SSEA, accounting for 32% (44) of 136
NNRTI SDRMs in this region.
Of the 40 PI SDRMs, nine were present in0.1% of the 46,819 viruses from all regions.
These nine SDRMs comprised 70% to 81% of PI SDRMs in each of the four regions: 72% (84)
of 117 PI SDRMs in SSA, 81% (64) of 79 PI SDRMs in SSEA, 84% (131) of 156 PI SDRMs in
Latin America/Caribbean, and 81% (795) of 986 PI SDRMs in the pooled upper-income coun-
tries. M46I/L, I85V, and L90M were the four most common PI SDRMs in SSA and SSEA, and
Fig 4. Temporal trends in the yearly proportion of individuals having one or more surveillance drug-
resistance mutations in low- andmiddle-income countries of south and southeast Asia. The x-axes
represent the number of years since ARV scale-up for each isolate. The diameter of each circle is
proportional to the number of samples sequenced that year. The fitted line shows the fixed effect of years
since ARV scale-up in generalized linear mixed model regression.
doi:10.1371/journal.pmed.1001810.g004
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among the six most common SDRMs in all regions. M46I was disproportionately more com-
mon in SSEA, where it accounted for 33% (26) of 79 PI SDRMs, compared with SSA (14%; 16
of 117; p< 0.001), Latin America/Caribbean (12%; 19 of 156; p< 0.001), and the pooled
upper-income countries (16%, 159 of 795; p< 0.001). M46L was not associated with a region,
accounting for 21% (24 of 117), 18% (14 of 79), 10% (16 of 156), and 12% (114 of 986) of PI
SDRMs in SSA, SSEA, Latin America/Caribbean, and the pooled upper-income countries, re-
spectively (S6 Table).
Correlation of Surveillance Drug-Resistance Mutations with Subtype
Of the 34 NRTI SDRMs, the T215 revertants accounted for a higher proportion of NRTI
SDRMs in subtype B viruses (24%; 725 of 2,920) than of viruses belonging to the remaining
subtypes (9%; 57 of 634; p< 0.001) (S7 Table). V75M accounted for a higher proportion of
NRTI SDRMs in CRF01_AE viruses compared with pooled viruses belonging to the remaining
subtypes (10% versus 1%; 16 of 157 versus 25 of 3,397; p< 0.001).
Of the 19 NNRTI SDRMs, Y181C accounted for a higher proportion of NNRTI SDRMs in
CRF01_AE viruses compared with pooled viruses belonging to the remaining subtypes (33%
versus 13%; 38 of 115 versus 212 of 1,631; p< 0.001) (S8 Table). K103N accounted for a higher
proportion of NNRTI SDRMs in subtype B viruses compared with pooled viruses belonging to
the remaining subtypes (53% versus 40%; 646 of 1,212 versus 214 of 534; p< 0.001). P225H ac-
counted for a higher proportion of NNRTI SDRMs in CRF02_AG viruses compared with
pooled viruses belonging to the remaining subtypes (14% versus 3%; nine of 65 versus 48 of
1,681; p< 0.001). V106M accounted for a higher proportion of genotypic NNRTI SDRMs in
Fig 5. Temporal trends in the yearly proportion of individuals having one or more surveillance drug-
resistance mutations in Latin America/Caribbean. The x-axes represent the calendar year of the sample.
The diameter of each circle is proportional to the number of samples sequenced that year. The fitted line
shows the fixed effect of sample year in generalized linear mixed model regression.
doi:10.1371/journal.pmed.1001810.g005
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subtype C viruses than in pooled viruses belonging to the remaining subtypes (5% versus 1%;
eight of 179 versus ten of 1,567; p< 0.001).
Of the 40 PI SDRMs, L23I (16%; eight of 51) accounted for a higher proportion of PI
SDRMs in subtype A viruses compared with pooled viruses belonging to the remaining sub-
types (1%; 11 of 1,267; p< 0.001) (S9 Table). Of the eight subtype A viruses with L23I, six were
part of a cluster of six sequences from one FSU study. F53Y accounted for a higher proportion
of PI SDRMs in subtype CRF02_AG compared with pooled viruses belonging to the remaining
subtypes (11% versus 1%; four of 37 versus seven of 1,281; p< 0.001). M46I, which was signifi-
cantly more common in individuals from SSEA, was not significantly associated with any sub-
type. The 17 individuals with M46I in SSEA included 11 subtype CRF01_AE, four subtype C,
and two subtype B viruses.
Correlation of Surveillance Drug-Resistance Mutations with Their
Prevalence in Treated Individuals
Among individuals with at least one SDRM, 21% of 501 individuals in SSA, 24% of 247 individ-
uals in SSEA, 37% of 439 individuals in Latin America/Caribbean, and 36% of 2,508 individuals
in the pooled upper-income countries had multiple SDRMs. In contrast, among ARV-experi-
enced patients with at least one SDRM in HIVDB, 83% of 4,028 individuals in SSA, 92% of
1,880 individuals in SSEA, 92% of 3,458 individuals in Latin America/Caribbean, and 86% of
11,279 individuals in the pooled upper-income countries had more than one SDRM.
The proportion of individuals with each NRTI SDRM was highly correlated with published
proportions of these mutations in NRTI-experienced individuals from the same region: SSA,
Fig 6. Temporal trends in the yearly proportion of individuals having one or more surveillance drug-
resistance mutations in North America. The x-axes represent the calendar year of the sample. The
diameter of each circle is proportional to the number of samples sequenced that year. The fitted line shows
the fixed effect of sample year in generalized linear mixed model regression.
doi:10.1371/journal.pmed.1001810.g006
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rho = 0.76 (p< 0.001); SSEA, rho = 0.77 (p< 0.001); Latin America/Caribbean, rho = 0.67
(p< 0.001); and the pooled upper-income countries, rho = 0.66 (p< 0.001) (Fig 9). The mean
proportions of the five most common NRTI SDRMs in NRTI-treated individuals was 65-fold
higher than their proportions in ARV-naïve individuals in SSA, 136-fold higher than in ARV-
naïve individuals in SSEA, 41-fold higher than in ARV-naïve individuals in Latin America/Carib-
bean, and 57-fold higher than in ARV-naïve individuals in the pooled upper-income countries.
The proportion of individuals with each NNRTI SDRMwas highly correlated with published
proportions of these mutations in NNRTI-experienced individuals from the same region: SSA,
rho = 0.72 (p< 0.001); SSEA, rho = 0.66 (p = 0.002); Latin America/Caribbean, rho = 0.84 (p<
0.001); and the pooled upper-income countries, rho = 0.87 (p< 0.001) (Fig 10). The mean pro-
portion of the five most common NNRTI SDRMs in NNRTI-treated individuals was 85-fold
higher than their proportion in ARV-naïve individuals in SSA, 122-fold higher than in ARV-
naïve individuals in SSEA, 24-fold higher than in ARV-naïve individuals in Latin America/Ca-
ribbean, and 39-fold lower in ARV-naïve individuals in the pooled upper-income countries.
The proportion of individuals with each PI SDRMwas correlated with published proportions
of these mutations in PI-treated individuals from the same region: SSA, rho = 0.61 (p< 0.001);
SSEA, rho = 0.38 (p = 0.02); Latin America/Caribbean, rho = 0.77 (p< 0.001), and the pooled
upper-income countries, rho = 0.88 (p< 0.001) (Fig 11). The mean proportion of the five most
common PI SDRMs in PI-treated individuals was 291-fold higher than their proportion in
ARV-naïve individuals in SSA, 388-fold higher than in ARV-naïve individuals in SSEA, 66-fold
higher than in ARV-naïve individuals in Latin America/Caribbean, and 65-fold higher than in
ARV-naïve individuals in the pooled upper-income countries. In all regions, the proportion of
PI-treated individuals with M46L or I85V divided by the number of ARV-naïve individuals with
Fig 7. Temporal trends in the yearly proportion of individuals having one or more surveillance drug-
resistance mutations in upper-income Asian countries. The x-axes represent the calendar year of the
sample. The diameter of each circle is proportional to the number of samples sequenced that year. The fitted
line shows the fixed effect of sample year in generalized linear mixed model regression.
doi:10.1371/journal.pmed.1001810.g007
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these SDRMs was much lower than the same proportion for all other commonly occurring
SDRMs.
Correlation of Surveillance Drug-Resistance Mutations with Estimated
Levels of Genotypic Resistance
Fig 12A shows the prevalence of resistance predicted by the HIVDB genotypic resistance inter-
pretation program to the NRTIs zidovudine, abacavir, lamivudine, and tenofovir using the
NRTI SDRMs; to the NNRTIs nevirapine, efavirenz, rilpivirine, and etravirine using the
NNRTI SDRMs; and to the PIs lopinavir, atazanavir, and darunavir using the PI SDRMs.
Predicted NRTI resistance ranged from 0.4% (tenofovir; 41 of 11,536) to 0.9% (zidovudine;
108 of 11,536) in SSA, 0.3% (tenofovir; 22 of 6,522) to 0.8% (zidovudine; 53 of 6,522) in SSEA,
and 1.4% (lamivudine; 419 of 30,663) to 4.2% (zidovudine; 1,297 of 30,663) in the pooled
upper-income countries and Latin America/Caribbean. Predicted lamivudine resistance was
usually high-level, caused by M184V/I. Predicted resistance to the other NRTIs was usually low
or intermediate. Predicted NNRTI resistance ranged from 0.9% (etravirine; 109 of 11,536) to
2.3% (nevirapine; 261 of 11,536) in SSA, 0.9% (etravirine; 61 of 6,522) to 1.7% (nevirapine and
efavirenz; 114 of 6,522) in SSEA, and 1.1% (etravirine; 326 of 30,663) to 3.6% (nevirapine;
1,089 of 30,663) in the pooled upper-income countries and Latin America/Caribbean. Nearly
all nevirapine resistance and about two-thirds of efavirenz resistance was predicted to be high-
level. Etravirine and rilpivirine resistance was usually caused by Y181C, a mutation selected
primarily by nevirapine. Predicted lopinavir, atazanavir, and darunavir resistance was less than
Fig 8. Temporal trends in the yearly proportion of individuals having one or more surveillance drug-
resistance mutations in Europe (and Israel). The x-axes represent the calendar year of the sample. The
diameter of each circle is proportional to the number of samples sequenced that year. The fitted line shows
the fixed effect of sample year in generalized linear mixed model regression.
doi:10.1371/journal.pmed.1001810.g008
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0.5% in SSA and SSEA. In Latin America/Caribbean and the pooled upper-income countries,
the estimated prevalence of lopinavir, atazanavir, and darunavir resistance was nearly 1%.
Fig 12B shows that few of the 48,722 virus samples without an NRTI SDRM were predicted
to have reduced NRTI susceptibility. However, among the 48,722 samples without NNRTI
SDRMs, 5.6% (644 of 11,536) of samples in SSA, 1.6% (104 of 6,522) in SSEA, and 2.6% (655 of
25,035) in the pooled upper-income countries were predicted to have low-level rilpivirine resis-
tance as a result of the polymorphic mutation E138A, which occurs in up to 6% of subtype A
and C viruses [34,35]. Nevirapine and efavirenz resistance were predicted in about 1% and
0.5% of virus samples without NNRTI SDRMs as a result of several minimally polymorphic
(e.g., A98G, V108I, and V179D) and rare nonpolymorphic (e.g., E138K, G190Q, F227C, and
K238T) NNRTI-resistance mutations. Many of the 45,883 samples without PI SDRMs had ac-
cessory polymorphic PI-resistance mutations. However, few samples had sufficient numbers of
these accessory mutations to reduce lopinavir, atazanavir, or darunavir susceptibility.
Molecular Phylogenetics
In studies conducted in SSA, Latin America/Caribbean, North America, Europe, and SSEA, the
median sequence dissimilarity index was 98%, 96%, 95%, 84%, and 80%, respectively (S3 Fig).
In the upper-income countries of Asia, the median sequence dissimilarity index was 65%. In
FSU countries, the median sequence dissimilarity index was 35%. Overall, 67 studies had two
or more closely related sequences with identical SDRMs. There would have been a median
Fig 9. The prevalence of each NRTI-associated surveillance drug-resistancemutation in this meta-
analysis versus in NRTI-experienced individuals in the same regions according to HIVDB. The
Spearman’s rank correlation coefficient (rho) and the p-value are shown in each plot. The number of isolates
from NRTI-experienced individuals were 4,522, 2,218, 4,164, and 13,522 for SSA, SSEA, Latin America/
Caribbean, and the pooled upper-income countries (UIC; Europe, North America, and upper-income Asian
countries), respectively.
doi:10.1371/journal.pmed.1001810.g009
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1.1% lower TDR prevalence in these studies had only one sequence from each set of closely re-
lated sequences been included in the analysis.
No study in SSA or SSEA contained an SDRM cluster (defined in the Methods as a set of
three or more closely related sequences with identical SDRMs), and only 19 pairs (5%; 38 of
763 viruses with TDR) of closely related sequences contained an identical SDRM in these two
regions. In Latin America/Caribbean, one study contained an SDRM cluster of three viruses
with the NNRTI SDRM K103N. In FSU countries, there was one SDRM cluster of six viruses
with the PI SDRM L23I, a nelfinavir-resistance mutation. In North America, Europe, and the
upper-income countries of Asia there were 22, 21, and 19 SDRM clusters, respectively. In these
three regions, the NNRTI SDRM K103N alone occurred in 22 clusters (96 individuals), a NRTI
SDRM T215 revertant alone occurred in 16 clusters (82 individuals), and the NNRTI SDRM
G190A alone occurred in five clusters (17 individuals). In addition to the large Japanese cluster
of PI SDRMM46I (30 individuals), there was one SDRM cluster of viruses from five individu-
als in North America with this mutation. There were seven SDRM clusters involving 39 indi-
viduals with more than one SDRM.
Discussion
This is to our knowledge the first individual-patient-level meta-analysis of TDR in HIV-1-in-
fected, ARV-naïve populations. HIV-1 RT (with or without protease) sequences from more
than 50,000 individuals from 287 studies were analyzed for geo-temporal trends in TDR preva-
lence using identical analytical methods for quality control, molecular phylogenetics,
Fig 10. The prevalence of each NNRTI-associated surveillance drug-resistance mutation in this meta-
analysis versus in NNRTI-experienced individuals in the same regions according to HIVDB. The
Spearman’s rank correlation coefficient (rho) and the p-value are shown in each plot. The number of isolates
from NNRTI-experienced individuals were 4,959, 1,994, 3,677, and 8,927 for SSA, SSEA, Latin America/
Caribbean, and the pooled upper-income countries (UIC; Europe, North America, and upper-income Asian
countries), respectively.
doi:10.1371/journal.pmed.1001810.g010
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mutational patterns, and predicted clinical significance. The availability of sequences from
each study participant made it possible to characterize the patterns of drug-resistance muta-
tions in individuals from different regions and in viruses of different subtypes, and to analyze
how often the same drug-resistance mutations were present in closely related virus sequences.
The 287 studies in this meta-analysis included 125 published studies of 25 or more ARV-
naïve individuals included in two previous meta-analyses [13,14] and 162 additional studies, in-
cluding 85 published between 2011 and 2013. HIV-1 RT sequence data were not available for
117 studies included in the two previous meta-analyses, including 22 studies from SSA, nine
from SSEA, ten from Latin America/Caribbean, 50 from Europe, 24 from North America, two
from upper-income Asian countries, and one from Australia. Therefore, of the combined 404
studies in this and the two previous meta-analyses, this meta-analysis includes 81% (95/117),
86% (56/65), 79% (38/48), 46% (42/92), 53% (27/51), and 86% (12/14) of the studies from SSA,
SSEA, Latin America/Caribbean, Europe, North America, and the upper-income Asian coun-
tries, respectively. In 2012, WHO published a report summarizing the results of 82 surveys of
3,588 individuals in 30 LMICs between 2004 and 2010 using theWHOHIV Drug Resistance
Threshold Survey targeting individuals recently infected with HIV-1 [11,36]. Sequences for 21 of
these surveys were publicly available by February 2014 and were included in this meta-analysis.
The median overall TDR prevalence in SSA and SSEA was 2.8% and 2.9%, respectively.
There was an estimated 1.1-fold yearly increase in the odds of overall, NRTI-associated, and
NNRTI-associated TDR in SSA since ARV scale-up began. In contrast, there was no significant
temporal change in the odds of TDR in SSEA since ARV scale-up began. The median overall
Fig 11. The prevalence of each PI-associated surveillance drug-resistancemutation in this meta-
analysis versus in PI-experienced individuals in the same regions according to HIVDB. The
Spearman’s rank correlation coefficient (rho) and the p-value are shown in each plot. The number of isolates
from PI-experienced individuals were 717, 103, 4,107, and 9,985 for SSA, SSEA, Latin America/Caribbean,
and the pooled upper-income countries (UIC; Europe, North America, and upper-income Asian
countries), respectively.
doi:10.1371/journal.pmed.1001810.g011
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TDR prevalence in upper-income Asian countries, Latin America/Caribbean, Europe, and
North America was 5.6%, 7.6%, 9.4%, and 11.5%, respectively. In both North America and Latin
America/Caribbean, there was an estimated 1.1-fold yearly increase in the odds of overall TDR
and a 1.2-fold yearly increase in the odds of NNRTI-associated TDR. In the upper-income
Fig 12. Estimated levels of predicted genotypic drug resistance for viruses with and without surveillance drug-resistance mutations. HIVDB
genotypic resistance interpretation program predictions of NRTI, NNRTI, and PI resistance for all virus samples using NRTI, NNRTI, and PI SDRMs,
respectively (A). HIVDB program predictions of NRTI, NNRTI, and PI resistance in all samples without an SDRM (B). NRTIs: zidovudine (AZT), abacavir
(ABC), lamivudine (3TC), and tenofovir (TDF); NNRTIs: nevirapine (NVP), efavirenz (EFV), rilpivirine (RPV), and etravirine (ETR); PIs: lopinavir (LPVr),
atazanavir (ATVr), and darunavir (DRVr). UIC, upper-income countries.
doi:10.1371/journal.pmed.1001810.g012
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Asian countries, there was an estimated 1.2-fold yearly increase in the odds of overall TDR and a
1.3-fold yearly increase in the odds of NNRTI- and PI-associated TDR. In Europe, there was a
0.9-fold yearly decrease in the odds of NRTI-associated TDR and a 1.1-fold yearly increase in
the odds of NNRTI-associated TDR.
A major limitation of the studies in our meta-analysis is their heterogeneity with respect to
the duration of infection prior to virus sampling. Many drug-resistance mutations reduce
HIV-1 replication fitness and recede to levels not detectable by standard genotypic resistance
testing in the absence of selective drug pressure. This occurs rapidly for the NRTI-resistance
mutation M184V, which recedes to undetectable levels at a rate of about 50% per year [37,38].
It occurs at a much slower rate of about 10% to 20% per year for most NNRTI-resistance muta-
tions and most TAMs [37,38]. Indeed, in our analysis, there was a particularly high correlation
between the prevalence of NNRTI SDRMs in ARV-naïve and ARV-experienced individuals in
the same region likely reflect the increased fitness, and hence stability, of NNRTI-resistance
mutations [39].
Several studies have shown that the proportion of sequence positions with a nucleotide mix-
ture increases with the duration of infection [26–28]. In our study, we found that more than
one-half of the sequences from studies of recently infected individuals did not contain a nucle-
otide mixture. The highest levels of nucleotide mixtures were in studies of individuals present-
ing to an HIV clinic whereas intermediate levels of nucleotide mixtures were detected among
blood donors, antenatal clinic attendees, and VCT attendees. An analysis limited to only those
sequences with less than 0.5% mixed nucleotides—a proxy for recent infection—yielded com-
parable trends to those obtained using the complete dataset reinforcing the trends reported in
this meta-analysis.
Endemic TDR strains emanating from a single instance of ARV-selection pressure that
spread among many individuals have different public health implications from TDR strains
emanating from multiple independent episodes of ARV-selection pressure [40–42]. Endemic
strains may carry a greater risk of ongoing transmission reflecting their ability to persist in a
population in the absence of selective drug pressure. In contrast, increasing TDR resulting
from multiple separate episodes of ARV-selection pressure can be mitigated by reducing the
risk of virological failure in patients on therapy.
To study whether TDR strains were likely to have arisen independently, we estimated the
extent of sequence clustering in each study and determined whether each drug-resistant virus
was part of a sequence cluster that contained other viruses with the same mutation. Of the 763
drug-resistant variants in SSA and SSEA, 19 pairs of viruses (n = 38; 5%) were closely related to
one another. In contrast, the remaining 725 viruses (95%) were not closely related to one an-
other. Although many of these viruses may be closely related to viruses that were not sampled,
phylogenetic analysis of the sequences in each study from SSA and SSEA suggests that most
TDR variants in this meta-analysis arose independently.
In SSA and SSEA, 89% of NNRTI-associated SDRMs were associated with high-level resis-
tance to nevirapine or efavirenz, whereas only 27% of NRTI SDRMs was associated with high-
level resistance to zidovudine, lamivudine, tenofovir, or abacavir. Several studies also suggest
that transmitted NNRTI resistance is more likely than transmitted NRTI resistance to cause vi-
rological failure on a first-line NRTI/NNRTI-containing regimen [15,16,20,43,44]. Should
NNRTI-associated TDR continue to increase, the inability to predict whether patients will re-
spond to an initial NRTI/NNRTI-containing regimen would undermine confidence in the
treatability of HIV-1 in LMICs and weaken the HIV care continuum. The point at which such
a loss of confidence would occur is difficult to predict but it would likely occur well below
thresholds at which cost-effectiveness models predict that a reduction in efficacy for entire
populations [45].
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The resources and capacity to perform HIV-1 drug resistance testing in LMICs are limited
and, where available, are concentrated in a few central laboratories. In addition, the infrastruc-
ture in many LMICs does not support the expansion in the number of these laboratories or the
rapid transportation of samples to these laboratories. The finding that a few mutations were re-
sponsible for 80% of NNRTI-associated TDR in all regions and subtypes should motivate the
development of inexpensive point-of-care point mutation assays for use in LMIC regions
[46,47]. Even in the context of a public health approach to ARV therapy, where few standard-
ized regimens are available at the population level, a reliable point-of-care genotypic resistance
test could identify which patients should receive standard first-line therapy and which should
receive a PI-containing regimen.
TDR surveillance of both newly infected individuals and patients presenting for ARV thera-
py informs treatment guidelines and diagnostic strategies particularly in regions where routine
genotypic resistance testing is not affordable [48]. This study demonstrates that sequence anal-
ysis is an important component of TDR surveillance because it yields insights into the molecu-
lar epidemiology of TDR and the specific drug-resistance mutations responsible for TDR. The
finding that most of the TDR strains in SSA and SSEA arose independently suggests that the
use of ARV regimens with a high genetic barrier to resistance combined with improved patient
adherence will mitigate the increase in TDR by reducing the generation of new ARV-resistant
strains [49]. The finding that a few NNRTI-resistance mutations were responsible for most
cases of transmitted high-level resistance suggests that inexpensive diagnostic point-mutation
assays for these NNRTI-resistance mutations may be useful for pre-therapy screening in those
LMIC regions with the highest levels of TDR.
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S1 Fig. Time-scaled analysis indicating an extended lineage of 30 individuals with viruses
containing the PI SDRMM46I from two studies conducted in Japan. Bayesian phylogenetic
inference of time-measured trees was performed using Markov chain Monte Carlo (MCMC)
sampling implemented in BEAST v.1.8.0. The substitution process was modeled according to
the general time-reversible substitution model with discrete gamma rate variation among sites.
An exponential growth model was specified as coalescent tree prior. Independent MCMC anal-
yses were run for 10 million generations, sampling every 5,000 generations, and the first 10%
of the samples was discarded as burn-in before combining the samples. The runs were investi-
gated based on effective sample size calculated using Tracer. Then a maximum clade credibility
tree was selected from the posterior tree distribution and visualized using FigTree. The values
at the nodes represent posterior support values (posterior probability) for the clusters. Viruses
containing M46I are labeled in red.
(EPS)
S2 Fig. Time-scaled analysis indicating an extended lineage of 16 individuals with viruses
containing the PI SDRMM46L alone from two studies conducted in Japan. Bayesian phylo-
genetic inference of time-measured trees was performed using MCMC sampling implemented
in BEAST v.1.8.0. The substitution process was modeled according to the general time-revers-
ible substitution model with discrete gamma rate variation among sites. An exponential growth
model was specified as coalescent tree prior. Independent MCMC analyses were run for 10 mil-
lion generations, sampling every 5,000 generations, and the first 10% of the samples was dis-
carded as burn-in before combining the samples. The runs were investigated based on effective
sample size calculated using Tracer. Then a maximum clade credibility tree was selected from
the posterior tree distribution and visualized using FigTree. The values at the nodes represent
posterior support values (posterior probability) for the clusters. Viruses containing M46L are
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index was defined in the Methods. The horizontal line indicates the median sequence dissimi-
larity index of the studies in each region. Regions are SSA, SSEA, Latin America/Caribbean,
FSU, upper-income Asian countries (UIC-Asia), Europe, and North America.
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Editors' Summary
Background
About 35 million people are currently infected with HIV, the virus that causes AIDS by de-
stroying immune system cells and leaving infected individuals susceptible to other infections.
Early in the AIDS epidemic, most HIV-infected individuals died within ten years of infec-
tion. Then, in 1996, effective antiretroviral (ARV) therapy—drug combinations that sup-
press HIV replication by inhibiting reverse transcriptase and other essential viral enzymes—
became available. For people living in affluent countries, HIV/AIDS became a chronic con-
dition, but because ARV therapy was expensive, HIV/AIDS remained fatal in low- and mid-
dle-income countries (LMICs). In 2003, the international community began to work
towards achieving universal access to ARV therapy. Now, more than 10 million HIV-posi-
tive individuals in LMICs receive ARV therapy, usually as a fixed-dose combination of two
nucleoside reverse transcriptase inhibitors (NRTIs), such as tenofovir and lamivudine, plus a
non-nucleoside reverse transcriptase inhibitor (NNRTI), such as efavirenz or nevirapine.
WhyWas This Study Done?
The global scale-up of ARV therapy has reduced deaths from HIV/AIDS and the incidence
of HIV infection in LMICs, but the development of resistance to ARV therapy is threaten-
ing these advances. HIV rapidly accumulates genetic changes (mutations), some of which
make HIV resistant to ARV therapy. Up to 30% of patients receiving a fixed-dose NRTI/
NNRTI combination develop virological failure, and a high proportion of these patients
develop mutations associated with resistance to the ARVs in their regimen. Moreover, the
proportion of newly infected, ARV-naïve individuals with transmitted drug resistance
(TDR) is also increasing. Organizations involved in HIV/AIDS control need to understand
the regional and temporal mutational patterns of TDR to inform the development of
guidelines for first-line ARV therapy and of inexpensive resistance mutation assays for use
in LMICs. Here, using a statistical approach called meta-analysis to combine information
from individual patients about the resistance mutations they carry, the researchers investi-
gate the molecular epidemiology of TDR (the patterns of molecular changes underlying
TDR in populations) and identify the HIV drug-resistance mutations most responsible for
TDR in different world regions.
What Did the Researchers Do and Find?
The researchers identified 287 studies published between 2000 and 2013 from 111 coun-
tries that included the reverse transcriptase sequences of HIV viruses from 50,870 ARV-
naïve, HIV-positive individuals. The researchers analyzed each virus sequence for the
presence of 93 surveillance drug-resistance mutations (SDRMs) previously shown to be
specific indicators of TDR. Meta-analysis of these data indicated that the average overall
prevalence of TDR (the proportion of ARV-naïve, HIV-positive individuals infected with
a virus carrying one or more SDRMs) ranged from 2.8% in sub-Saharan Africa to 11.5% in
North America. In sub-Saharan Africa, the odds (chance) of TDR increased 1.09-fold per
year following national ARV scale-up; this increase was attributable to an increase in
NRTI- and NNRTI-associated resistance. By contrast, in LMICs in south/southeast Asia,
the odds of TDR remained unchanged following ARV scale-up. In Latin America/Caribbe-
an, North America, Europe, and upper-income Asian countries, the odds of TDR have
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increased by around 1.10-fold per year since 1995, mainly as a result of increased NNRTI
resistance. Four NNRTI-associated and 16 NRTI-associated SDRMs accounted for most
NNRTI- and NRTI-associated TDR, respectively, in all regions. Notably, in sub-Saharan
Africa and south/southeast Asia, most of the NNRTI-associated SDRMs detected were as-
sociated with high-level resistance to nevirapine or efavirenz. Finally, the researchers re-
port that 95% of TDR viruses in sub-Saharan Africa and south/southeast Asia were
unrelated and had therefore arisen independently.
What Do These Findings Mean?
Because many drug-resistance mutations reduce HIV’s fitness and tend to be lost rapidly
in individuals not exposed to ARV therapy, differences among the datasets used in this
meta-analysis with respect to how long each ARV-naïve patient had been infected with
HIV before virus sampling may limit the accuracy of these findings. Nevertheless, the find-
ing that most of the TDR strains detected in sub-Saharan Africa and south/southeast Asia
arose independently suggests that improved patient adherence to ARV therapy and the
use of ARV regimens that contain drugs to which HIV rarely develops resistance (regi-
mens with a high genetic barrier to resistance) should reduce the generation of new ARV-
resistant strains and mitigate TDR increases. In addition, the finding that a few NNRTI-re-
sistance mutations were responsible for most cases of transmitted high-level resistance
suggests that an inexpensive assay that detects these specific mutations may be useful for
pre-therapy screening in LMICs with high TDR levels.
Additional Information
Please access these websites via the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001810.
• Information is available from the US National Institute of Allergy and Infectious Dis-
eases on HIV infection and AIDS
• NAM/aidsmap provides basic information about HIV/AIDS, summaries of recent research
findings on HIV care and treatment, and personal stories about living with HIV/AIDS
• Information is available from Avert, an international AIDS charity, on many aspects of
HIV/AIDS, including information on antiretroviral drugs and on universal access to
ARV therapy; Avert also provides personal stories about living with HIV/AIDS
• TheWorld Health Organization provides information on all aspects of HIV/AIDS (in
several languages), including its guidelines on the use of antiretroviral therapy for
treating and preventing HIV infection
• The UNAIDSWorld AIDS Day Report 2014 provides up-to-date information about the
AIDS epidemic and efforts to halt it, including progress towards universal access to
antiretroviral therapy
• The Stanford University HIV Drug Resistance Database includes information about
surveillance drug-resistant mutations (SDRMs) and an interactive map displaying HIV
drug resistance in ARV-naïve populations
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